The application of gene therapy to treat human disorders has made many advances in recent years, although many ethical challenges associated with this type of intervention remain unresolved. This
Jan 16, 2020 · Evaluating the safety and potential activity of URO‐902 (hMaxi‐K) gene transfer by intravesical instillation or direct injection into the bladder wall in female participants with idiopathic (non‐neurogenic) overactive bladder syndrome and detrusor overactivity from two double‐blind, imbalanced, placebo‐controlled randomized phase 1 trials Mar 18, 2016 · Patients given the two highest doses of hMaxi-K had apparent sustained improvements in erectile function as indicated by improved IIEF domain scores over the length of the study. This was a small study, but the encouraging safety profiles and effectiveness provide evidence that gene therapy is a viable option for the future. results of a phase i hmaxi-k gene transfer trial for erectile dysfunction Article in European Urology Supplements 5(2):140-140 · April 2006 with 35 Reads How we measure 'reads' Jul 02, 2020 · Since 2018, the date of the last update of EAU guidelines, important information concerning oral and intervention therapies for non-neurogenic LUTS was reported. Mirabegron was shown to be effective and safe across all age groups and both sexes. Vibegron was extensively studied for the first time, enriching the beta-3 class. The application of gene therapy to treat human disorders has made many advances in recent years, although many ethical challenges associated with this type of intervention remain unresolved. This
DESCRIPTION (provided by applicant): This grant application is by Ion Channel Innovations, LLC, (ICI) a company dedicated to the development of naked DNA transfer to treat the unmet needs of people with common smooth muscle diseases that negatively impactthe quality of life of millions.
hMaxi-K has been evaluated in two Phase 1 studies in OAB patients including a Urovant disclaims any obligation to update these forward-looking statements, except as may be required by law. Sep 24, 2018 · Urovant's second product candidate, hMaxi-K, is a novel gene therapy being developed for patients with OAB who have failed oral pharmacological therapy. Urovant intends to develop treatments for Aug 28, 2018 · - Urovant expects to initiate Phase 2 hMaxi-K study in 2019 BASEL, Switzerland and IRVINE, Calif., Aug. 28, 2018 /PRNewswire/ -- Urovant Sciences , a clinical-stage biopharmaceutical company focused on developing therapies for urologic conditions, today announced it has licensed a novel investigational gene therapy for patients with overactive
Evaluating the safety and potential activity of URO‐902 (hMaxi‐K) gene transfer by intravesical instillation or direct injection into the bladder wall in female participants with idiopathic (non‐neurogenic) overactive bladder syndrome and detrusor overactivity from two double‐blind, imbalanced, placebo‐controlled randomized phase 1 trials
hMaxi-K gene therapy - Sumitovant Biopharma Alternative Names: hMaxi-K - Ion Channel Innovations; hMaxi-K; pVAX/hSlo; URO-902 Latest Information Update: 06 Feb 2020 Patients given tlie two highest doses of hMaxi-K had apparent sustained improvements in erectile function (EF) as indicated by improved HEF-EF domain scores over the length of the study. One Jan 16, 2020 · Evaluating the safety and potential activity of URO‐902 (hMaxi‐K) gene transfer by intravesical instillation or direct injection into the bladder wall in female participants with idiopathic (non‐neurogenic) overactive bladder syndrome and detrusor overactivity from two double‐blind, imbalanced, placebo‐controlled randomized phase 1 trials